
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed's operating margin improved by 80 basis points year-over-year, primarily due to gross margin expansion, which saw an increase of 230 basis points year-over-year linked to pricing strategies, manufacturing efficiencies, and declining component costs. In addition, the company reported respiratory sales in the Americas of $749 million, marking a 12% increase, while the rest of the world saw a growth of 8% in respiratory sales, demonstrating strong demand amid a growing market for sleep apnea treatment. Furthermore, improvements in gross margins to 59.2%, supported by operational efficiencies and a favorable product mix, coupled with a positive outlook on CPAP patient growth, indicate significant potential for enhanced profitability in the upcoming year.
Bears say
ResMed's gross margin remained flat sequentially, indicating potential challenges in maintaining profitability amid competitive pressures. The company's organic revenue growth has decelerated, dropping to 10% in F2Q25 from 11% in the prior quarter, raising concerns about its ability to maintain market position. Additionally, the anticipated impact of GLP-1 weight loss drugs is expected to create headwinds, with lowered earnings estimates suggesting continued downward pressures on revenue growth and margins in the upcoming fiscal years.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares